Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ivarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired Resistance to Immune Checkpoint Therapy: A Single-Arm Exploratory Clinical Study

NCT07324473 is registered in ClinicalTrials.gov with First Affiliated Hospital of Chongqing Medical University as lead sponsor.

NCT NCT07324473
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07324473 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ivarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired Resistance to Immune Checkpoint Therapy: A Single-Arm Exploratory Clinical Study
Lead sponsor
First Affiliated Hospital of Chongqing Medical University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
January 1, 2026
Completion date
January 1, 2029
Enrollment
65 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

drug repurposing, hepatocellular carcinomas, immunomodulation, resistance to immunotherapy